Scott Ratzan, Eric C Schneider, Hilary Hatch, Joseph Cacchione
New England Journal of Medicine, Volume 384, Issue 25, June 2021.
May 5, 2021: New England Journal of Medicine
Noa Dagan, Noam Barda, Eldad Kepten, Oren Miron, Shay Perchik, Mark A Katz, Miguel A Hernán, Marc Lipsitch, Ben Reis, Ran D Balicer
BACKGROUND: As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. In this study, data from Israel's largest health care organization were used to evaluate the effectiveness of the BNT162b2 mRNA vaccine. METHODS: All persons who were newly vaccinated during the period from December 20, 2020, to February 1, 2021, were matched to unvaccinated controls in a 1:1 ratio according to demographic and clinical characteristics...
February 24, 2021: New England Journal of Medicine
Patrick R Lawler, Ewan C Goligher, Jeffrey S Berger, Matthew D Neal, Bryan J McVerry, Jose C Nicolau, Michelle N Gong, Marc Carrier, Robert S Rosenson, Harmony R Reynolds, Alexis F Turgeon, Jorge Escobedo, David T Huang, Charlotte Ann Bradbury, Brett L Houston, Lucy Z Kornblith, Anand Kumar, Susan R Kahn, Mary Cushman, Zoe McQuilten, Arthur Slutsky, Keri S Kim, Anthony C Gordon, Bridget-Anne Kirwan, Maria M Brooks, Alisa M Higgins, Roger J Lewis, Elizabeth Lorenzi, Scott M Berry, Lindsay R Berry, Derek C Angus, Colin J McArthur, Steven A Webb, Michael E Farkouh, Judith S Hochman, Ryan Zarychanski
Background Thrombo-inflammation may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic-dose anticoagulation may improve outcomes in non-critically ill patients hospitalized for Covid-19. Methods In an open-label adaptive multiplatform randomized controlled trial, non-critically ill patients hospitalized for Covid-19, defined by the absence of critical care-level organ support at enrollment, were randomized to a pragmatic strategy of therapeutic-dose anticoagulation with heparin or usual care pharmacological thromboprophylaxis...
0: medRxiv: the preprint server for health sciences
(no author information available yet)
No abstract text is available yet for this article.
April 14, 2021: JAMA
Andreas Greinacher, Thomas Thiele, Theodore E Warkentin, Karin Weisser, Paul A Kyrle, Sabine Eichinger
BACKGROUND: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder. METHODS: We assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19...
April 9, 2021: New England Journal of Medicine
Eric J Rubin, Lindsey R Baden, Stephen Morrissey
New England Journal of Medicine, Volume 384, Issue 8, February 2021.
February 25, 2021: New England Journal of Medicine
Anthony C Gordon, Paul R Mouncey, Farah Al-Beidh, Kathryn M Rowan, Alistair D Nichol, Yaseen M Arabi, Djillali Annane, Abi Beane, Wilma van Bentum-Puijk, Lindsay R Berry, Zahra Bhimani, Marc J M Bonten, Charlotte A Bradbury, Frank M Brunkhorst, Adrian Buzgau, Allen C Cheng, Michelle A Detry, Eamon J Duffy, Lise J Estcourt, Mark Fitzgerald, Herman Goossens, Rashan Haniffa, Alisa M Higgins, Thomas E Hills, Christopher M Horvat, Francois Lamontagne, Patrick R Lawler, Helen L Leavis, Kelsey M Linstrum, Edward Litton, Elizabeth Lorenzi, John C Marshall, Florian B Mayr, Daniel F McAuley, Anna McGlothlin, Shay P McGuinness, Bryan J McVerry, Stephanie K Montgomery, Susan C Morpeth, Srinivas Murthy, Katrina Orr, Rachael L Parke, Jane C Parker, Asad E Patanwala, Ville Pettilä, Emma Rademaker, Marlene S Santos, Christina T Saunders, Christopher W Seymour, Manu Shankar-Hari, Wendy I Sligl, Alexis F Turgeon, Anne M Turner, Frank L van de Veerdonk, Ryan Zarychanski, Cameron Green, Roger J Lewis, Derek C Angus, Colin J McArthur, Scott Berry, Steve A Webb, Lennie P G Derde
BACKGROUND: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS: We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight), sarilumab (400 mg), or standard care (control)...
February 25, 2021: New England Journal of Medicine
Ivan O Rosas, Norbert Bräu, Michael Waters, Ronaldo C Go, Bradley D Hunter, Sanjay Bhagani, Daniel Skiest, Mariam S Aziz, Nichola Cooper, Ivor S Douglas, Sinisa Savic, Taryn Youngstein, Lorenzo Del Sorbo, Antonio Cubillo Gracian, David J De La Zerda, Andrew Ustianowski, Min Bao, Sophie Dimonaco, Emily Graham, Balpreet Matharu, Helen Spotswood, Larry Tsai, Atul Malhotra
BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort studies. Data are needed from randomized, placebo-controlled trials. METHODS: In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab (at a dose of 8 mg per kilogram of body weight) or placebo...
February 25, 2021: New England Journal of Medicine
Daniel B Kramer, Douglas J Opel, Efthimios Parasidis, Michelle M Mello
New England Journal of Medicine, Volume 384, Issue 17, April 2021.
April 29, 2021: New England Journal of Medicine
Gillian K SteelFisher, Robert J Blendon, Hannah Caporello
New England Journal of Medicine, Volume 384, Issue 16, Page 1483-1487, April 2021.
April 22, 2021: New England Journal of Medicine
Christopher J L Murray, Peter Piot
No abstract text is available yet for this article.
March 3, 2021: JAMA
Max A Schumm, Joseph E Hadaya, Nisha Mody, Bethany A Myers, Melinda Maggard-Gibbons
Importance: The COVID-19 pandemic has resulted in a persistent shortage of personal protective equipment; therefore, a need exists for hospitals to reprocess filtering facepiece respirators (FFRs), such as N95 respirators. Objective: To perform a systematic review to evaluate the evidence on effectiveness and feasibility of different processes used for decontaminating N95 respirators. Evidence Review: A search of PubMed and EMBASE (through January 31, 2021) was completed for 5 types of respirator-decontaminating processes including UV irradiation, vaporized hydrogen peroxide, moist-heat incubation, microwave-generated steam, and ethylene oxide...
March 3, 2021: JAMA
John P Moore
No abstract text is available yet for this article.
April 6, 2021: JAMA
Carlos Del Rio, Preeti Malani
No abstract text is available yet for this article.
March 4, 2021: JAMA
Eduardo López-Medina, Pío López, Isabel C Hurtado, Diana M Dávalos, Oscar Ramirez, Ernesto Martínez, Jesus A Díazgranados, José M Oñate, Hector Chavarriaga, Sócrates Herrera, Beatriz Parra, Gerardo Libreros, Roberto Jaramillo, Ana C Avendaño, Dilian F Toro, Miyerlandi Torres, Maria C Lesmes, Carlos A Rios, Isabella Caicedo
Importance: Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit. Objective: To determine whether ivermectin is an efficacious treatment for mild COVID-19. Design, Setting, and Participants: Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state's health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period...
March 4, 2021: JAMA
Leon Boudourakis, Amit Uppal
No abstract text is available yet for this article.
April 1, 2021: JAMA Internal Medicine
Valerie Smith, Declan Devane, Alistair Nichol, David Roche
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the strain of coronavirus that causes coronavirus disease 2019 (COVID-19) can cause serious illness in some people resulting in admission to intensive care units (ICU) and frequently, ventilatory support for acute respiratory failure. Evaluating ICU care, and what is effective in improving outcomes for these patients is critical. Care bundles, a small set of evidence-based interventions, delivered together consistently, may improve patient outcomes...
December 21, 2020: Cochrane Database of Systematic Reviews
Edmund Huang, Stanley C Jordan
New England Journal of Medicine, Volume 383, Issue 24, Page 2387-2388, December 2020.
December 10, 2020: New England Journal of Medicine
Eric J Rubin, Dan L Longo
New England Journal of Medicine, Volume 383, Issue 27, Page 2677-2678, December 2020.
December 31, 2020: New England Journal of Medicine
Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, Kay M Tomashek, Cameron R Wolfe, Varduhi Ghazaryan, Vincent C Marconi, Guillermo M Ruiz-Palacios, Lanny Hsieh, Susan Kline, Victor Tapson, Nicole M Iovine, Mamta K Jain, Daniel A Sweeney, Hana M El Sahly, Angela R Branche, Justino Regalado Pineda, David C Lye, Uriel Sandkovsky, Anne F Luetkemeyer, Stuart H Cohen, Robert W Finberg, Patrick E H Jackson, Babafemi Taiwo, Catherine I Paules, Henry Arguinchona, Paul Goepfert, Neera Ahuja, Maria Frank, Myoung-Don Oh, Eu S Kim, Seow Y Tan, Richard A Mularski, Henrik Nielsen, Philip O Ponce, Barbara S Taylor, LuAnn Larson, Nadine G Rouphael, Youssef Saklawi, Valeria D Cantos, Emily R Ko, John J Engemann, Alpesh N Amin, Miki Watanabe, Joanne Billings, Marie-Carmelle Elie, Richard T Davey, Timothy H Burgess, Jennifer Ferreira, Michelle Green, Mat Makowski, Anabela Cardoso, Stephanie de Bono, Tyler Bonnett, Michael Proschan, Gregory A Deye, Walla Dempsey, Seema U Nayak, Lori E Dodd, John H Beigel
BACKGROUND: Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS: We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control)...
December 11, 2020: New England Journal of Medicine
2020-12-23 23:05:45
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"